The hepatitis c crisis

Ethnicity and Disease

Volumn 15, Issue 2 SUPPL. 2, 2005, Pages

  St John, Tina M ^a   Sandt, Lorren ^b,c  

^a Caring Ambassadors Program   (United States)

^b Hepatitis C Caring Ambassadors Program   (United States)

^c Hepatitis C Caring Ambassadors Program   (United States)

Author keywords

Antibodies; Chronic hepatitis C; Hepatitis C; Hepatocellular Carcinoma; Liver Cirrhosis; Liver Transplantation

Indexed keywords

EID: 61849145821     PISSN: 1049510X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (41)

1. World Health Organization. Hepatitis C. 2000. Fact Sheet No. 164. Available at: www.who.int/mediacentre/factsheets/fs 164. Accessed October 15, 2004.
2. Centers for Disease Control and Prevention. National Hepatitis C Prevention Strategy: a comprehensive strategy for the prevention and control of hepatitis C virus infection and its consequences. Available at: www.cdc.gov/ncidod/diseases/hepatitis/c/plan/index.htm. Accessed October 15, 2004.
3. Centers for Disease Control and Prevention. Updated US Public Health Service guidelines on the management of occupational exposure to HBV, HCV, and HIV and recommendations for post-exposure prophylaxis. MMWR. 2001;50:1-67.
4. Kingsley LA, Detels R, Kaslow R, et al. Risk factors for seroconversion to human immunodeficiency virus among male homosexuals. Results from the Multicenter AIDS Cohort Study. Lancet. 1987;1:345-349.
5. Landesman SH, Kalish LA, Burns DN, et al. Obstetrical factors and the transmission of HIV type 1 from mother to child. N Engl J Med. 1996;334:1617-1623.
6. Zanetti AR, Tanzi E, Paccagnini S, et al. Mother to infant transmission of hepatitis C virus. Lancet. 1995;345:289-291.
7. Thomas DL, Villano SA, Riester KA, et al. Perinatal transmission of hepatitis C virus from HIV type 1 infected mothers. J Infect Dis. 1998;177:1480-1488.
8. Eyster ME, Alter HJ, Aledorr LM, Quan S, Hatzakis A, Goedert JJ. Heterosexual corransmission of hepatitis C virus and human immunodeficiency virus. Ann Intern Med. 1991;115:764-768.
9. Verucchi G, Calza L, Manfredi R, Chiodo F. Human immunodeficiency virus and hepatitis C virus coinfection: epidemiology, natural history, therapeutic options, and clinical management. Infection. 2004;32(l):33-46.
10. Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C vims infection in the United States, 1988 through 1994. N Engl J Med. 1999;341:556-562.
11. CDC. Prevention and control of infections with hepatitis viruses in correctional settings. MMWR Recomm Rep. 2003;52(RR-l):l-36.
12. Nyamathi AM, Dixon EL, Robbins W, et al. Risk factors for hepatitis C virus infection among homeless adults. J Gen Intern Med. 2002; 17(2): 134-143.
13. Bica I, McGovern B, Dhar R, et al. Increasing mortality due to end-stage livet disease in patients with human immunodeficiency virus infection. Clin Infect Dis. 2001;32:492-497.
14. Alter MJ. Epidemiology of hepatitis C in the West. Semin Liver Dis. 1995;15(1):5-14.
15. National Institutes of Health Consensus Development Conference Panel. Management of hepatitis C. NIH Consensus Statement. 1997; 15(3):1-41.
16. National Institutes of Health Consensus Development Conference Panel. Statement: management of hepatitis C. Hepatology. 1997; 26(suppl 1):2S-10S.
17. Yano M, Kumada H, Kage M, et al. The long-term pathological evolution of chronic hepatitis C. Hepatology. 1996;23(6):1334-1340.
18. Di Bisceglie AM. Hepatitis C and hepatocellular carcinoma. Hepatology. 1997;26(suppl 1):34S-38S.
19. Amarapukar D. Natural history of hepatitis C virus infection. J Gastroenterol Hepatol. 2000; 15(suppl E):105-110.
20. Lucidarme D, Dumas E Arpurt JP, et al. Rapid progress of cirrhosis in hepatitis C: the role of age at the time of viral contamination. Presse Med. 1998;27:608-611.
21. Bortolotti F, Faggion S, Con P. Natural history of chronic viral hepatitis in childhood. Acta Gastroenterol Belg. 1998;61:198-201.
22. Kuboki M, Shinzawa H, Shao L, et al. A cohort study of hepatitis C virus (HCV) infection in an HCV epidemic area of Japan: age and sex-relared seroprevalence of anti-HCV antibody, frequency of viremia, biochemical abnormality and histological changes. Liver. 1999;19:88-96.
23. Alric L, Fort M, Izopet J, et al. Study of host and virus-related factors associated with spontaneous hepatitis C virus clearance. Tissue Antigens. 2000;56:154-158.
24. Inoue G, Horiike N, Michitaka K, Onji M. Hepatitis C virus clearance is prominent in women in an endemic area. J Gastroenterol Hepatol. 2000;15:1054-1058.
25. Yamakawa Y, Sata M, Suzuki H, Noguchi S, Tanikaawa K. Higher elimination rate of hepatitis C virus among women. J Viral Hepat. 1996;3:317-321.
26. Datz C, Cramp M, Haas T et al. The natural course of hepatitis C virus infection 18 years after an epidemic outbreak of non-A, non-B hepatitis in a plasmapheresis centre. Gut. 1999;44:563-567.
27. Alberti A, Chemello L, Benvegnu L. Natural history of hepatitis C. J Hepatol. 1999; 31(suppl 1): 17-24.
28. Hourigan LF, Macdonald GA, Purdie D, et al. Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. Hepatology. 1999;29:1215-1219.
29. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet. 1997; 349(9055):825-832.
30. Conry-Cantilena C, VanRaden M, Gibble J, et al. Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection. N Engl J Med. 1996; 334(26): 1691-1696.
31. Blatt LM, Mutchnick MG, Tong MJ, et al. Assessment of hepatitis C virus RNA and genotype from 6807 patients with chronic hepatitis C in the United States. J Viral Hepat. 2000;7(3): 196-202.
32. Cromie SL, Jenkins PJ, Bowden DS, Dudley FJ. Chronic hepatitis C: effect of alcohol on hepatitic activity and viral titre. J Hepatol. 1996;25(6):821-826.
33. Saadeh S, Cammell G, Carey WD, Younossi Z, Barnes D, Easley K. The role of liver biopsy in chronic hepatitis C. Hepatology. 2001; 33(l):196-200.
34. Falck-Ytter Y, Kale H, Mullen KD, Sarbah SA, Sorescu L, McCullough AJ. Surprisingly small effect of antiviral treatment in patients with hepatitis C. Ann Intern Med. 2002; 136(4):288-292.
35. Cawthorne CH, Rudat KR, Burton MS, et al. Limited success of HCV anriviral therapy in United States veterans. Am J Gastroenterol. 2002;97(1):149-155.
36. Yawn BP, Wollan P, Gazzuola L, Kim WR. Diagnosis and 10-year follow-up of a community-based hepatitis C cohort. J Farn Pract. 2002;51(2):135-140.
37. Muir AJ, Provenzale D. A descriptive evaluation of eligibility for therapy among veterans with chronic hepatitis C virus infection. J Clin Gastroenterol. 2002;34(3):268-271.
38. Leigh JP, Bowlus CL, Leistikow BN, Schenker M. Costs of hepatitis C. Arch Intern Med. 2001;161(18):2231-2237.
39. Kochanek KD, Murphy SL, Anderson RN, Scott C. Deaths: final data for 2002. Natl Vital Stat Rep. 2004;53(5).T-116.
40. Centers for Disease Control and Prevention. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR. 1998; 47:1-39.
41. Wong JB, McQuillan GM, McHutchison JG, Poynard T. Estimating furure hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health. 2000;90:1562-1569.